Poster Open Access

Advances in understanding and drug development for ALK2/ACVR1 gain of function mutations in Diffuse Intrinsic Pontine Glioma (DIPG)

Wong, Jong Fu; Brown, Elizabeth; Williams, Eleanor; Adamson, Ros; Farnie, Gillian; Boudhar, Aicha; Brennan, Paul E; Edwards, Aled M; Bullock, Alex N

A poster outlining the program being undertaken within the Structural Genomics Consortium to co-develop drugs for both Diffuse Intrinsic Pontine Glioma (DIPG) and Fibrodysplasia Ossificans Progressiva (FOP).

The following topics are covered: prevalency of ALK2/ACVR1 mutations in DIPG, the crystal structure of the ALK2-FKBP12 complex, the increased BMP pathway activity in ALK2 mutants, the M4K Pharma ALK2 inhibitor development workflow and the M4K mission statement "Affordable Meds 4 Kids".

Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files (885.9 kB)
Name Size
885.9 kB Download
All versions This version
Views 163163
Downloads 206205
Data volume 182.5 MB181.6 MB
Unique views 149149
Unique downloads 203202


Cite as